Contact CFFC


Clinical Trial Alerts – December 2018

Cystic Fibrosis Foundation distributed the following clinical trial updates in December. Click the trial title to get more details.

OPTION: Study of AzurRx MS1819 in people with cystic fibrosis and exocrine pancreatic insufficiency who are 18 years and older

Status: Enrolling

Description: This trial will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 30% or greater

Number of Visits: 10

Length of Participation: 11 weeks link:

OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin

Status: Completed with results

Description: This study evaluated the effect of treatment with tobramycin inhalation solution (TIS) with and without azithromycin in people with CF who had their first isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture (or their first culture after being negative for Pa for at least 2 years).

Age: 6 Months to 18 Years

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 8

Length of Participation: 18 months link:

Comments are closed.